REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Stack Library

Lean Body Recomp

Fat Lossbeginner
44
Peptides

2

Avg Daily mcg

500

Level

beginner

Added

May 16, 2026

Overview

The Lean Body Recomp is a streamlined, beginner-friendly peptide stack engineered for efficient fat loss while preserving lean muscle tissue. By combining AOD-9604, a modified fragment of human growth hormone specifically targeting lipolysis, with Ipamorelin, a selective growth hormone secretagogue, this protocol attacks body fat through dual metabolic pathways without the side effects associated with full-length GH administration. AOD-9604 at 300mcg daily is derived from the fat-burning region of the growth hormone molecule (amino acids 177-191) and has been shown to stimulate lipolysis and inhibit lipogenesis without affecting blood sugar levels or promoting tissue growth. Unlike full-length HGH, it does not cause insulin resistance, water retention, or joint pain, making it an ideal targeted fat-loss agent. Ipamorelin at 200mcg daily complements this by stimulating clean, physiological GH pulses that enhance metabolic rate, support muscle protein synthesis, and improve sleep quality, all of which contribute to favorable body recomposition. The synergy in this stack is elegant: AOD-9604 directly mobilizes stored fat for oxidation while Ipamorelin maintains the anabolic and metabolic environment needed to prevent muscle catabolism during a caloric deficit. The result is a shift in body composition rather than simple weight loss. For optimal results, administer AOD-9604 in the morning on an empty stomach, at least 30 minutes before eating, to maximize its lipolytic window. Ipamorelin is best taken before bed on an empty stomach (no food for 2 hours prior) to amplify nocturnal GH release. Avoid high-fat meals within an hour of either injection. This stack is suited for beginners looking to reduce body fat percentage while maintaining or slowly building lean mass. It works best when paired with a moderate caloric deficit (300-500 calories below maintenance), regular resistance training, and adequate protein intake. Research on AOD-9604 has demonstrated fat reduction without appetite changes, while Ipamorelin studies confirm selective GH release without cortisol or prolactin elevation. Typical cycles run 8-12 weeks.

Dosing Protocol

AOD-9604

Every day

300 mcg

per dose

Ipamorelin

Every day

200 mcg

per dose

Goals & Evidence

Evidence tier:community

Disclaimer: This stack is community-submitted and for research purposes only. PeptideVault does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.